You are in: eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology Apnea of PrematurityArticle Last Updated: Sep 4, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Dharmendra J Nimavat, MD, FAAP, Assistant Professor of Clinical Pediatrics, Department of Pediatrics, Southern Illinois University School of Medicine Dharmendra J Nimavat is a member of the following medical societies: American Academy of Pediatrics and American Association of Physicians of Indian Origin Coauthor(s): Michael P Sherman, MD, Professor, Department of Pediatrics, Southern Illinois University School of Medicine; Professor Emeritus, Department of Pediatrics, University of California, Davis School of Medicine; Neonatologist, St John's Children's Hospital and Decatur Memorial Hospital; Rene L Santin, MD, Consulting Staff, Department of Pediatrics, Division of Neonatology, Primary Care Centers of Eastern Kentucky; Rachel Porat, MD, Director, Neonatal Apnea Monitoring Program, Assistant Director, Division of Neonatology, Albert Einstein Medical Center; Associate Professor, Department of Pediatrics, Thomas Jefferson University Editors: Steven M Donn, MD, Professor of Pediatrics, Director, Neonatal-Perinatal Medicine, Department of Pediatrics, University of Michigan Health System; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Arun K Pramanik, MD, Professor, Department of Pediatrics, Division of Neonatology, Louisiana State University Health Science Center; Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina; Ted Rosenkrantz, MD, Head, Division of Neonatal-Perinatal Medicine, Professor, Departments of Pediatrics and Obstetrics/Gynecology, University of Connecticut School of Medicine Author and Editor Disclosure Synonyms and related keywords: AOP, fetal breathing, pauses in the fetal breathing pattern, pathologic apnea, central apnea, obstructive apnea, mixed apnea, apnea of infancy, AOI, neonatal apnea, premature newborn, premature neonate, premature baby, premature babies, premature infant, premature birth, preemies, absence of breathing, cessation of breathing, periodic breathing, PB, sudden infant death syndrome, SIDS, crib death, cot death INTRODUCTIONBackgroundOverview of the current state of knowledgeOur understanding of the anatomy, physiology, biochemistry, and molecular biology of neonatal breathing has increased in recent years.1, 2, 3, 4 For instance, emerging data are elucidating the genes involved in the embryonic development of central respiratory centers and their neural networks.5 The central respiratory generator is essential for fetal breathing movements. It appears early in pregnancy and importantly contributes to pulmonary development.6 In the fetus, breathing is intermittent and occurs during the low-voltage electrocortical state (analogous to rapid eye movement [REM] sleep) and becomes continuous immediately after birth. The regulatory neurologic mechanisms that cause the transition from intermittent fetal breathing to continuous neonatal breathing are incompletely appreciated.7, 8 After birth, apnea of prematurity (AOP) is a major concern for caregivers in intensive care nurseries. The magnitude of this problem resulted in the National Institutes of Child Health and Human Development (NICHD) convening a workshop on AOP. Summary Proceedings from the Apnea-of-Prematurity Group have been published.9 The NICHD review group emphasized the following conclusions:
The NICHD review group also made recommendations about what issues associated with AOP that need urgent attention, what research methods might be best for future studies, what outcomes are essential to our understanding of AOP, and what ethical principles should govern future investigations of AOP. Given this discussion from the NICHD review group, the present article provides state-of-the-art information regarding what is and what is not known about AOP. DefinitionsApnea and its classification Apnea is defined as the cessation of breathing for more than 20 seconds or apnea or the cessation of breathing for less than 20 seconds if it is accompanied by bradycardia or oxygen (O2) desaturation.10, 9
These definitions represent clinically significant changes in apnea, bradycardia, and O2 saturation changes and rarely occur in healthy preterm neonates older than 36 weeks after conception. Apnea is classified as central, obstructive, or mixed.
Apnea of infancy Apnea of infancy (AOI) occurs when apnea persists in a neonate older than 37 weeks after conception. The physiologic aspects of AOP and AOI coincide, though further studies are needed to determine their exact relationship. Periodic breathing Periodic breathing is defined as periods of regular respiration for as long as 20 seconds followed by apneic periods of 10 seconds or less that occur at least 3 times in succession (see Media file 3). Periodic breathing may be observed for 2-6% of the breathing time in healthy term neonates and as much as 25% of the breathing time in preterm neonates. The occurrence of periodic breathing is directly proportional to the degree of prematurity. Kelly and coworkers (1979) observed periodic breathing in 78% of neonates examined at 0-2 weeks of age.11 The incidence substantially declined to 29% at the postconceptual ages of 39-52 weeks. Periodic breathing typically does not occur in neonates during their first 2 days of life. Periodic breathing most frequently occurs during active sleep, but it can also happen when neonates are awake or quietly sleeping. This pattern, commonly observed in patients at high altitudes, is eliminated with supplemental oxygenation and/or with the use of continuous positive airway pressure (CPAP). Because the prognosis is excellent and because the infant is not compromised, no treatment is usually required. PathophysiologyCentral respiratory regulation Immaturity and/or depression of the central respiratory drive to the muscles of respiration have been accepted as key factors in the pathogenesis of AOP.1 Vulnerability of the ventral surface of the medulla and adjacent areas in the brainstem to inhibitory mechanisms is the likely explanation for why apneic episodes occur in prematurely born infants. This vulnerability involves diverse clinicopathologic events.12, 4 Inhibitory events that affect the central respiratory generator and initiate apnea include hypoxia, hyperthermia and adenosine secretion.13 Studies of preterm infants and in animals (especially genetically altered mice) have enhanced our understanding of the molecular and biochemical events leading to maturation of the central respiratory generator in preterm infants.2, 3, 14, 15 Using noninvasive techniques, Henderson-Smart and coworkers (1983) documented that brainstem conduction times of auditory-evoked responses were longer in infants with apnea than in matched premature infants without apnea.16 This study elucidated apnea in preterm infants by indirectly showing that infants with apnea had greater-than-expected immaturity of brainstem function, which was based on postconceptional age. This finding supports the concept than an immature brainstem eventually develops control of breathing as dendritic spines and synaptic connections mature. An observation that emphasizes the importance of the central respiratory generator is the finding of increased apnea among preterm infants with bilirubin-encephalopathy diagnosed by using abnormal auditory brainstem-evoked responses.17 The absence of respiratory muscle activity during central apnea unequivocally implicates depression of respiratory center output. In support of this concept, Gauda and associates (1989) documented reduced electromyographic activity in the diaphragm during spontaneous obstructed inspiratory efforts.18 Such efforts characterize combined central and obstructive apnea.19 Therefore, episodes of both central and mixed apneic share an element of decreased respiratory center output to the respiratory muscles. Sleep state and apnea Apnea during infancy occurs most frequently during active or REM sleep.20, 21 Apnea occurs relatively infrequently during quiet sleep, when respiration is characteristically regular, with little breath-to-breath variation in tidal volume and respiratory rate. However, periodic breathing may predominantly occur during non-REM sleep. During active sleep, respiration is mostly paradoxical due to spinal motoneural inhibition of the activity of intercostal muscles.22 In extremely preterm infants, the paucity of quiet sleep, together with an extremely compliant rib cage, makes paradoxical chest-wall movements almost a constant phenomenon. Paradoxical chest movement may predispose the baby to apnea by decreasing functional residual capacity (FRC) and limiting oxygenation.23 Chemoreceptors and mechanoreceptors Complex relationships exist between respiratory control; several sites of central chemosensitivity to carbon dioxide (CO2) during sleep; and various neuromechanical factors originating in the lungs, chest wall, and upper airway that modify respiratory function during sleep.24 Responses of chemoreceptors in preterm and term neonates were recently reviewed.25, 26, 27 The response to elevated CO2 concentrations was blunted in prematurely born infants. This diminished response may partly be due to decreased central chemosensitivity or mechanical factors that prevent an adequate ventilatory response.28, 29 The slope of the response curve for CO2 is decreased for preterm infants who have apnea.30 However, a cause-and-effect relationship between decreased CO2 responsiveness and AOP has not been clearly established. Administration of CO2 ameliorates periodic breathing, but inhalation of CO2 is not a therapeutic option for human infants. For many years, scientists have known that preterm infants respond to a decrease in inspired O2 concentration with a transient increase in ventilatory response, followed by return to baseline or even depression of ventilation.31 This response to low O2 in infants appears to result from initial stimulation of peripheral chemoreceptors then overriding depression of the respiratory center as a result of hypoxemia.32 Consistent with these findings is the observation that a progressive decrease in inspired O2 concentrations causes a significant flattening of CO2 responsiveness in preterm infants.33 This unstable response to low inspired O2 levels may play an important role in the origin of neonatal apnea. It offers a physiologic rationale for the decrease in incidence of apnea observed when a slightly increased concentration of inspired O2 is administered to infants with apnea.34 The Hering-Breuer reflex also plays an important role in modulating respiratory timing in human neonates. Pulmonary stretch receptors send an afferent neural input to brain and mediate the Hering-Breuer reflex by means of the vagus nerve. Thereafter, they inhibit inspiration, prolong expiration, or both, while increasing lung volume.23 Active shortening of expiratory duration with decreased lung volume may provide a breathing strategy for preserving FRC in a neonate with a highly compliant chest wall. Upper airway obstruction substantially contributes to apneic episodes in preterm infants, and upper airway muscles show preferential reflex activation in response to airway obstruction in infants.35 Gerhardt and Bancalari compared the ability of preterm infants with and those without apnea to respond to end-expiratory airway occlusion.36, 30 Prolongation of the occluded inspiratory effort was significantly prolonged in the group without apnea. This finding suggested that this group had a relatively mature respiratory reflex response that improved their ability to respond to airway obstruction. In premature infants, complex changes in pulmonary mechanics and ventilatory timing accompany apnea.37 Before apnea occurs, total pulmonary resistance may increase in association with a decrease in tidal volume and prolongation of the expiratory time. Such changes have been noted before episodes of mixed, obstructive, and central apnea. In 1982, Waggener and coworkers showed that a diminution in respiratory drive precedes apnea, a finding reminiscent of the cyclic alterations in respiratory drive.38 After apnea resolves and respiration resumes, the respiratory drive in premature infants initially increases, possibly because of a cumulative effect of hypoxia and hypercapnia. Total pulmonary and supraglottic resistance also increases, perhaps in response to a decrease in lung volume and collapse of the upper airway when respiratory drive declines during the apnea. Of note, within 2 or 3 breaths after apnea, pulmonary resistance and respiratory drive is restored to normal pre-apnea values in premature infants. Therefore, the neural systems that restore respiratory homeostasis appear to be capable of mounting an adequate response, even in premature infants with apnea. Upper airway instability and muscles of the chest wall Premature infants have pharyngeal or laryngeal obstruction during spontaneous apnea. Thach (1983) proposed a model in which the negative luminal pressures generated during inspiration in the upper airway predispose a compliant pharynx to collapse.39 Many muscles of the upper airway, especially the genioglossus muscles, have been widely implicated in mixed and obstructive apnea affecting both infants and adults. In 1988, Carlo, Martin, and Difiore compared the activity of the genioglossus muscles with that of the diaphragm in response to hypercapnic stimulation.40 In preterm infants, genioglossus activation was delayed for about one minute after CO2 rebreathing was begun, and it occurred only after a CO2 threshold of approximately 45 mm Hg was reached. In neonates inspiratory time is often modestly prolonged when end-expiratory airway occlusion prevents lung inflation. As indicated earlier, this effect is a manifestation of the Hering-Breuer reflex. Studies in animals demonstrated that this vagally mediated inhibition of normal lung inflation has more influence on the upper airway muscles than on the diaphragm.41 Upper airway reflexes The upper airway contains many sensory nerve endings that may respond to variety of chemical and mechanical stimuli. Sensory input from these upper airway receptors travels to the CNS by means of cranial nerves V, VI, IX, X, XI, and XII. They may strongly affect respiratory rate and rhythm, heart rate, and vascular resistance.42 The chemoreceptor drive may augment the ability of the upper airway muscles to respond to increasing negative pressure, whereas input from pulmonary stretch receptors inhibits it.43 Swallowing during the respiratory pause is unique to apnea and does not occur during periodic breathing.44 Effects of adenosine Adenosine and its analogs cause respiratory depression.45 Adenosine antagonism is proposed as a mechanism to explain the therapeutic effect of aminophylline.46 Gastroesophageal reflux GER and apnea are common in preterm infants. Because they often coexist, a lively and ongoing debate persists among healthcare professionals about the role of GER in AOP. An extensive literature review was undertaken to justify arguments about the role of GER in AOP. Monitoring studies demonstrated that, when a relationship between reflux and apnea is observed, apnea may precede rather than follow reflux.47, 48 During an apneic episode, loss of respiratory neural output may be accompanied by a decrease in lower esophageal tone, and GER occurs. This phenomenon is supported by data from a newborn piglet model, which showed that hypoxia and apnea were accompanied by a reduction in lower esophageal sphincter pressure, which was a predisposing factor for GER.49 GER and apnea are also discussed in Differentials and in Controversies related to AOP under Special Concerns. FrequencyUnited StatesAlthough not always apparent, AOP is the most common problem in premature neonates.9 Approximately 70% of babies born before 34 weeks of gestation have clinically significant apnea, bradycardia, or O2 desaturation during their hospital stay. The more immature the infant, the higher his or her risk of AOP. Apnea may occur during the postnatal period in 25% of neonates who weighed less than 2500 g at birth and in 84% of neonates who weigh less than 1000 g. Carlo (1982) and Barrington (1990) showed that apnea may begin on the first day of life in neonates without respiratory distress syndrome.50, 51 However, AOP is always a diagnosis of exclusion. Many diseases manifest with apnea on the day of birth; examples are intrapartum magnesium exposure, systemic infections or the fetal inflammatory response syndrome, pneumonia, intracranial pathology, seizures, hypoglycemia, and other metabolic disturbances. Approximately 50% or more of surviving infants who weighed less than 1500 g at birth have episodes of apnea that must be managed with pharmacologic intervention or ventilatory support. Mixed apnea accounts for about 50% of all cases of apnea in premature neonates; about 40% are central apneas, and 10% are obstructive apneas.52 These percentages vary in different reports. In 50% of all apneic episodes, an obstructive component precedes or follows central apnea, which leads to mixed apnea. InternationalTo the authors' knowledge, no investigators have compared the incidence of AOP in the United States with those of other countries. Mortality/MorbidityButcher-Puech and coworkers (1985) found that infants in whom obstructive apnea exceeded 20 seconds had an increased incidence of intraventricular hemorrhage, hydrocephalus, prolonged mechanical ventilation, and abnormal neurologic development after their first year of life.53 In 1985, Perlman and Volpe described a decrease in the cerebral blood flow velocity that accompanies severe bradycardia (heart rate <80 bpm).54 Infants with clinically significant AOP do not perform as well as prematurely born infants without recurrent apneas during neurodevelopmental follow-up testing.55, 56 RaceThe authors know of no systematic, prospective clinical study that has been conducted to evaluate the role of a person's race or ethnic background on the incidence of AOP. SexTo the authors' awareness, no systematic, prospective clinical study has been performed to evaluate the role of a person's sex on the incidence of AOP. AgeA young gestational age at birth is associated with an increased incidence of AOP. The age at which AOP resolves depends on several factors. The mean time for severe AOP to resolve is approximately 43 weeks after conception, but a prolonged duration of risk is not uncommon. 10 In one report, about 6-22% of babies with a very low birth weight had apnea at term.57 Approximately 91% of premature neonates had apnea of longer than 12 seconds at the time of hospital discharge. Of these babies, 31% also had bradycardia, and 6.5% required prolonged hospitalization because of the severity of their apnea and bradycardia. These findings show that AOP does not resolve at term in many low-birth-weight infants and that it may persist for some time after hospital discharge. CLINICALHistoryInitial identification and assessment of apnea The bedside caregivers—namely, the nurse in the neonatal intensive care unit (NICU) the respiratory care practitioner—identify the problem for the physician. Apnea should be distinguished from periodic breathing and documented. Use of a cardiorespiratory monitor is essential for identifying apnea of prematurity (AOP) and for monitoring the patient's blood pressure. Events associated with apnea, such as bradycardia and cyanosis, must be quantified. For bradycardia, the magnitude of reduction in heart rate from baseline and the duration of the event should be recorded. The presence and duration of central cyanosis should also be noted. Pulse oximetry may be helpful for measuring the severity and duration of central O2 desaturation. Caregivers should be aware of the problems associated with the use of pulse oximetry to evaluate O2 saturation.58 When apnea is observed, its duration must be established. Cardiorespiratory monitors can be used to quantify the duration. Caregivers should attempt to define the type and severity of the patient's apnea. The type of apnea is identified as central, obstructive, or mixed. A nasal thermistor may be needed in conjunction with pneumography to differentiate the type of apnea. Classification of the severity of apnea Criteria to classify the severity of apnea have not been well developed in clinical studies. The University of Washington published indications for different treatments based on the severity of AOP.59 This classification for AOP uses the terms spontaneous, mild, moderate, or severe.
Clinical centers must develop the classification system they wish to use to measure the severity of apnea. Factors often used to judge the need for future interventions include these:
The therapeutic approach used in most NICUs involves a progression from tactile stimulation to methylxanthine therapy and then some form of assisted breathing (eg, nasal continuous airway pressure or assisted ventilation). Exclusion of other causes of apnea Before a diagnosis of AOP is made, other causes of apnea in neonates must be excluded (see Differentials). All forms of apnea may be difficult to detect visually, though obstructive apnea is usually most obvious to a trained observer. Cardiorespiratory monitoring and pulse oximetry have improved bedside detection of AOP.60 Caregivers should familiarize themselves with the advantages and disadvantages of cardiorespiratory monitoring and pulse oximetry in neonates. Published findings show that even highly trained observers miss more than 50% of AOP episodes. Precise diagnosis of AOP requires multichannel recordings, which are most commonly measurements of nasal airflow, thoracic impedance, heart rate, and O2 saturation. Expanded testing may include electroencephalography and/or use of an esophageal pH probe with a high thoracic Clark electrode. Hydrochloric acid may be added to the feedings to increase the gastric concentration of hydrogen ions. PhysicalPhysical examination should include observation of the infant's breathing patterns while he or she is asleep and awake. The prone or supine sleeping positions and other lying postures may be important during this clinical observation. Important to the assessment of neonatal apnea is the identification of airway abnormalities (eg, choanal obstruction, anomalies of the palate, jaw deformities, neck masses) and conditions in distant organs that influence breathing (eg, brain hemorrhages, seizures, pulmonary disorders, congenital heart disease). Findings in the head and neck and other obvious major and minor anomalies identified may suggest chromosomal abnormalities or a malformation syndrome. Appropriate work-up must then follow. Physical examination includes the elements described below:
CausesThe physiology related to AOP is reviewed in Pathophysiology. Aspects of causation are briefly reemphasized here. A premature neonate in whom all other causes of apnea have been excluded may be considered to have AOP. Although the etiology of AOP is not fully understood, several mechanisms have been proposed to explain this condition, including those described below.
DIFFERENTIALSAnemia of Prematurity Neonatal Sepsis Respiratory Failure Respiratory Syncytial Virus Infection
|
| Drug Name | Aminophylline (Aminophyllin) |
|---|---|
| Description | Indications include AOP (eg, apnea after extubation from assisted ventilation, apnea after general anesthesia, apnea during use of prostaglandin E1 to treat ductal-dependent heart defects). Stimulates central respiratory drive and peripheral chemoreceptor activity; may increase diaphragmatic contractility. Aminophylline salt is 78.9% theophylline; theophylline PO is 80% bioavailable. May need to adjust dose when changing from IV aminophylline to PO theophylline. In neonates, aminophylline significantly (30-80%) interconverted to caffeine. IV and PO forms effective in about 80-85% of infants with central apnea. |
| Pediatric Dose | Based on aminophylline (ie, not theophylline equivalent) Loading dose: 4-8 mg/kg PO or IV over 30 min Maintenance dose: 1.5-3 mg/kg/dose PO q8-12h or slow IV bolus q8-12h; start 8-12 h after loading dose Therapeutic theophylline serum concentration (trough) for AOP is 7-12 mcg/mL; target theophylline serum concentration is 10-20 mcg/mL for bronchospasm in older infants (ie, some infants with bronchopulmonary dysplasia) |
| Contraindications | Documented hypersensitivity; uncontrolled arrhythmias; peptic ulcers; hyperthyroidism; uncontrolled seizure disorders |
| Interactions | Aminoglutethimide, barbiturates, carbamazepine, ketoconazole, loop diuretics, charcoal, hydantoins, phenobarbital, phenytoin, rifampin, isoniazid, and sympathomimetics may decrease effects of theophylline; allopurinol, beta-blockers, ciprofloxacin, corticosteroids, disulfiram, quinolones, thyroid hormones, ephedrine, carbamazepine, cimetidine, erythromycin, macrolides, propranolol, and interferon may increase effects of theophylline May be associated with renal calcifications when used concurrently with furosemide and/or dexamethasone IV incompatible with amiodarone, cefotaxime, ceftriaxone, clindamycin, dobutamine, epinephrine, hydralazine, insulin, isoproterenol, methadone, methylprednisolone, penicillin G, and phenytoin Solution compatible with 5% or 10% dextrose in water and normal saline Terminal injection site compatible with dextrose and amino acid solutions, lipid emulsions, acyclovir, ampicillin, amikacin, aztreonam, calcium gluconate, cefazolin, ceftazidime, dexamethasone, dopamine, enalaprilat, erythromycin lactobionate, famotidine, fluconazole, furosemide, heparin, hydrocortisone succinate, isoproterenol, lidocaine, methicillin, meropenem, metronidazole, midazolam, morphine, nafcillin, nitroglycerin, nitroprusside, pancuronium bromide, pentobarbital, phenobarbital, piperacillin, potassium chloride, prostaglandin E1, ranitidine, sodium bicarbonate, ticarcillin/clavulanate, tobramycin, vancomycin, and vecuronium |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Emphasize slow IV infusion because changes in cerebral blood flow may occur Caution with peptic ulcers, hypertension, tachyarrhythmias, hyperthyroidism, and compromised cardiac function; increased risk of toxicity in pulmonary edema or liver dysfunction because of reduced clearance; periodically monitor heart rate and blood glucose; consider withholding next dose if heart rate >180 bpm; may produce GI irritation, hyperglycemia, CNS irritability, and sleeplessness; signs of toxicity include sinus tachycardia, failure to gain weight, vomiting, jitteriness, hyperreflexia, and seizures |
| Drug Name | Caffeine citrate (Cafcit) |
|---|---|
| Description | Indications include AOP (eg, apnea after extubation from assisted ventilation, apnea after general anesthesia). Therapeutic index more favorable than that of aminophylline. Increases output of respiratory center, sensitivity of chemoreceptor to CO2, smooth muscle relaxation, and cardiac output. Serum half-life 40-230 h, which declines until 60-wk postmenstrual age. |
| Pediatric Dose | Loading dose: 20-40 mg/kg PO or IV over 30 min (equivalent to 10-20 mg/kg caffeine base) Maintenance dose: 5-8 mg/kg PO qd or slow IV bolus starting 24 h after loading dose (equivalent to 2.5-4 mg/kg caffeine base) Therapeutic trough serum concentrations 5-25 mcg/mL; measure trough levels 5 d after start of therapy; serum concentration >40-50 mcg/mL is toxic |
| Contraindications | Documented hypersensitivity; products containing sodium benzoate |
| Interactions | Antagonizes actions of adenosine; may reduce clearance of theophylline by 25% and cause additive pharmacologic effects (decrease dose); additive positive inotropic and chronotropic effects may occur with beta-adrenergic agonists; cimetidine and fluconazole decrease clearance, increasing serum levels; phenytoin induces hepatic metabolism, decreasing half-life and increasing clearance; increases metabolism of phenobarbital and increases own metabolism Incompatible with acyclovir, furosemide, lorazepam, oxacillin, and nitroglycerin Solution compatible with 5% or 10% dextrose in water and normal saline Terminal injection site compatible with dextrose and amino acid solutions, lipid emulsions, calcium gluconate, cefotaxime, cimetidine, clindamycin, dexamethasone, dobutamine, dopamine, epinephrine, fentanyl, gentamicin, heparin (<1 U/mL), isoproterenol, lidocaine, morphine, nitroprusside, pancuronium, penicillin G, phenobarbital, sodium bicarbonate, and vancomycin |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May increase O2 consumption and decrease weight gain; do not administer dose if heart rate persistently >180 bpm; functional cardiac symptoms (eg, extrasystoles) possible; restlessness and vomiting can be signs of toxicity; cholestatic hepatitis may prolong serum half-life |
Apnea-free interval before discharge
Most neonatologists agree that babies should be apnea-free for 2-10 days before discharge. However, the interval between the last apneic event and a safe time for discharge is not clearly established. The minimum apnea-free period is debated among clinicians. Darnall et al (1997) concluded that otherwise healthy preterm neonates continue to have periods of apnea separated by as many as 8 days before the last episode of apnea before discharge.122 Infants with long intervals between apneic event often have risk factors other than apnea of prematurity (AOP).
Home monitoring
Home monitoring after discharge is necessary for infants whose apneic episodes continue despite the administration of methylxanthine. Infants undergoing methylxanthine therapy rarely are sent home without a monitor because apnea may recur after they outgrow their therapeutic level. Without a monitor, caregivers may not know when apnea reappears.
Some families cannot manage monitoring in the home. In these cases, the administration of caffeine may be the only possible therapy. Infants in this situation need frequent follow-up visits, and they should be readmitted for further evaluation when their blood levels approach the subtherapeutic range.
Home monitoring
Various agencies and organizations have stated that home monitoring cannot prevent sudden infant death syndrome (SIDS), also called crib death or cot death, in preterm infants who have AOP during their hospitalization.10, 9
Indications for home monitoring
Home monitoring may be indicated in the situations described below.
The National Institutes of Health (NIH) consensus conference recommends monitoring for the siblings of infants with SIDS, but only after 2 SIDS-related deaths occur in a family. Physicians often begin monitoring after one sibling dies from SIDS; this practice may be related to a fear of litigation should another child in the family die from SIDS. Siblings of patients who died from SIDS are routinely monitored until one month past the patient's age at death.
Monitoring is not indicated to prevent SIDS in infants older than one year, though proponents believe that such monitoring reduces anxiety in the parents of high-risk infants. Opponents of monitoring cite a lack of evidence to show that monitoring reduces the rate of SIDS. They argue that monitors intrude on the family's life and that they are poorly tolerated by the family.10
Types of monitors
Several types of cardiorespiratory monitors are available for home use in the United States. The most common type combines impedance pneumography with an assessment of the patient's mean heart rate. The most notable drawback of impedance monitors is their inability to detect obstructive apnea. Newer monitors can minimize false alarms caused by motion artifact.
Standard home monitors detect respiratory signals and heart rates. Electrodes are placed directly on the infant's chest or inside an adjustable belt secured around his or her chest.
Monitoring units should be capable of recording cardiac and respiratory data because this information can help the physician in evaluating the need to stop medication or monitoring. These devices also record compliance with monitor use. The event recorder contains a computer chip that continuously records respiratory and cardiac signals. Normal signals are erased, but any event that deviates from preset parameters activates the monitor to save records of that event, as well as data 15-75 before and 15-75 seconds it. Additional channels are available to record pulse oximetry readings, nasal airflow, and body position (eg, prone vs supine). The records are downloaded within 24 hours after a parent reports an event or after excessive alarms occur.
Many units now have computer modems that instantly transmit data to the physician's office for evaluation. These easily installed devices are especially useful for families who have had problems with events or alarms.
Some devices, such as pulse oximeters, piezo belts, and pressure capsules, have been impractical to use or have had limited applications. Newer technologies and software programs may soon make such oximeters and similar devices more practical than they once were.
All monitoring devices are associated with false alarms, which are alerts without in the absent of a true cardiorespiratory event. False alarms worry parents. If they happen often, they may discourage use of the monitor. Excessive false alarms can usually be minimized by adjusting the placement of the electrodes and by educating the parents.
Details of monitoring depend on the frequency of events observed during neonatal hospitalization, the size and stability of the infant at the time of discharge, and the degree of parental anxiety.
Follow-up of home monitoring and patient education
Careful follow-up is needed with all cases of home monitoring in prematurely born neonates. Physicians who have limited experience with home monitoring or who cannot interpret the downloaded recordings should seek assistance from a center or program with expertise in these areas.
The most important issue with monitoring is that Neonatal Resuscitation Program (NRP) instructors should educate parents, guardians, and other caregivers about neonatal resuscitation by using a mannequin before their child is discharged from the NICU.
Parents should also be educated about prenatal and postnatal factors associated with an increased risk of SIDS, namely, the following:123, 26
Parents must also be aware that postural skull deformities have occurred after the AAP offered positioning recommendations in its Back to Sleep campaign.124 Prematurely born infants are probably at increased risk. Ways to avoid or minimize skull deformities should be discussed with parents.
Parents of infants with home monitors must have a clearly designated person who they can contact on a regular basis and during emergencies. Many programs or centers provide 24-hour assistance for families of children with home monitors.
The mean duration of home monitoring for prematurely born neonates is often more than 6 weeks. Extended monitoring is reserved for infants whose recordings show notable cardiorespiratory abnormalities. Monitoring beyond age 1 year is uncommon. Most often, children who require such monitoring have other conditions that require the use of additional technology. An example is an infant with bronchopulmonary dysplasia who requires mechanical ventilation at home.
For infants who require therapy with a methylxanthine, drug therapy is typically stopped after 8 weeks without true events, but monitoring is continued for an additional 4 weeks.125, 126 If no events are noted in this period, monitoring can be discontinued. These recommendations regarding discontinuing methylxanthines or home monitoring are not based on data from controlled studies; these investigations are badly needed.
Infants born prematurely are at increased risk for apnea and bradycardia after undergoing general anesthesia or sedation with ketamine, regardless of their history of apnea. Because of this increased risk, defer elective surgery, if possible, until approximately 52-60 weeks after conception to allow the infant's respiratory control mechanism to mature.
Regarding the natural history of apnea in infants born prematurely, the frequencies of all types of apnea gradually decreases during the first months of postnatal life. However, in some infants, apnea may persist until the age of 44 weeks after conception.
An Internet search of the terms preterm infant, SIDS, and malpractice yields results linked to several law practices. Some of these sites tell parents that they should sue over the SIDS-related death of their preterm infant.
The medical literature is relatively silent about medical malpractice suits related to SIDS. The present authors know of malpractice cases involving infants who had apnea just days before discharge, who were discharged home without monitoring, and who then died at home or had an acute life-threatening event with brain injury. Even statements by national agencies that home monitoring cannot prevent SIDS have little impact when such malpractice cases go to a jury.
When an unanticipated death does occur at home, it must be properly investigated. The investigation should address the possibility of death from child abuse, as well as late deaths from unrecognized malformations or inborn errors of metabolism (eg, fatty acid oxidation disorders).127
Use of car seats or car beds
The AAP has indicated that a car-seat challenge should be performed before preterm infants are discharged from the hospital.128 The importance of this testing is emphasized in an AAP pamphlet called Car Safety Seats: A Guide for Families 2007, which is given to parents. It addressed issues related to car-seat safety during infancy.
Adverse events do happen when preterm infants are placed in car seats.129 However, authors of a Cochrane Review could not conclude whether car-seat testing with preterm infants was beneficial or detrimental. They did conclude that additional research was needed to evaluate its effectiveness in preventing the complications of apnea.130
If problems are found, treatment is another matter. Some have thought that if a preterm infant does not pass a car-seat challenge, they can be safely transported in a car bed. However, Salhab et al (2007) reported that apnea and other adverse events were as likely to occur in car beds as in car seats.131 A preterm infant riding in a car seat should be carefully observed by a caregiver.
Retinal examinations
In NICUs, preterm infants have had apneic events after retinal examinations. Although the drugs used to dilate the iris are implicated in these apneic events, the incidence and mechanisms associated with apnea have been poorly studied.
Use of a pacifier
Another belief is that a preterm infant is at increased risk for SIDS if they suckle a pacifier. Researchers have concluded that the opposite is true.132 Moreover, pacifiers do not affect breastfeeding in preterm infants.133 Pacifiers should obviously be removed from the mouth of a sleeping supine infant.
Hypermagnesemia
Studies reported decades ago demonstrated that hypermagnesemia secondary to maternal magnesium sulfate administration can cause apnea immediately after birth.72 Some neonatologists do not agree with this finding.
Methylxanthine therapy
Prophylactic versus intent-to-treat use of methylxanthines is another controversial subject. Some suggest prophylactic use of methylxanthines is indicated when very preterm infants are extubated to discontinue assisted ventilation. Older infants with a history of apnea of prematurity (AOP) may also benefit from prophylactic methylxanthines if they must undergo anesthesia for a surgical procedure.
Likewise, prophylactic therapy with methylxanthines might seem reasonable in preterm infants with birth weights less than 1000 g. Nevertheless, use of methylxanthines in preterm infants are being viewed with caution because of their effects on brain development.
Substantial disagreement exists among neonatologists regarding the criteria for stopping methylxanthine therapy, such as the numbers of days without apnea, bradycardia, or desaturation that are required. The discontinuation of methylxanthines may also depends on the patient's postconceptual age and other factors in an individual infant. Neonatologists are conflicted about what is considered safe in terms of the number of event-free days after a methylxanthine is stopped and the number of days without apnea before hospital discharge. Additional clinical research is urgently needed to resolve these issues.
Use of caffeine versus aminophylline
Despite the relatively broad therapeutic index, the use of caffeine versus aminophylline to treat AOP is still an unsettled issue with some neonatologists.
Home monitoring
To the authors' knowledge, no protocols to determine when a preterm infant with AOP should or should not have home monitoring have been evaluated in clinical trials.
Gastroesophageal reflux
Despite the overwhelming body of evidence that GER is not associated with apnea, many neonatologists still use agents to inhibit gastric acidity and thereby prevent apnea. This controversial issue in preterm infants with AOP has been discussed throughout this article.
Possible risk factors for SIDS or near-miss SIDS
SIDS and AOP
Infants born prematurely account for approximately 10% of the birth population, yet they experience slightly more than 20% of SIDS-related deaths. The immature respiratory control so commonly observed in premature neonates has led to suggestions of a relationship between AOP and SIDS.
Premature infants in NICUs often cease breathing unexpectedly. These events are frequently accompanied by bradycardia and O2 desaturation. In many instances, the infant might not have resumed breathing without direct intervention.
The hypothesis that apnea is a cause of SIDS is attractive because the premature neonate does not struggle to resume breathing. This situation appears to be similar to that noted in many cases of SIDS. However, this theory of SIDS causation has not been proven. Furthermore, according to parental reports, most infants who died from SIDS were full-term neonates who had no apparent apneic events before death. However, visual detection of apnea and periodic breathing typically is difficult, even for medical personnel, and parents may miss such episodes.
No evidence identifies AOP as an independent risk factor for SIDS, despite the ongoing controversy surrounding the relationship between apnea and SIDS. Despite all of their common factors, large-scale trials conducted to verify the relationship between AOP and SIDS have failed to delineate an abnormality of ventilatory control that underlies SIDS.
Prolonged apnea has been reported in infants with near-miss SIDS (ie, infants who have had an ALTE). Short episodes of apnea, periodic breathing, and mixed and obstructive apnea have been identified in infants with near-miss SIDS. These observations suggest that an abnormality in ventilatory control may contribute to SIDS. The risk of SIDS risk is highest among infants aged 2-4 months, similar to the risk for an ALTE. Positive family histories for these events are found for infants who die from SIDS and patients with apnea. Incidences of both conditions peak during cold weather months, and both typically occur while the infant is asleep.
Sleeping position
A reduction in postneonatal mortality and SIDS rates have been associated with sleeping in a supine position rather than a prone position. Several research groups have documented physiologic benefits with prone positioning versus supine positioning in preterm infants; advantages included a modest improvement in transcutaneously measured PO2, prolonged time in quiet sleep, decreased energy expenditure, and increased ventilatory responses to inspired CO2. However, recent studies indicated that prone sleeping may increase the risk of SIDS after hospital discharge.134, 135 The increased risk of SIDS appears related to fewer arousals and more central apnea with prone versus supine sleeping.
To decrease the incidence of SIDS, the AAP has recommended placing healthy neonates on their backs, instead of prone, for sleeping.123 The mechan